Skip to main content
SpringerLink
Log in

ATenativ® — ein hochreines Antithrombinkonzentrat

Hintergrund, Forschung, klinische Bewertung und Herstellung

  • Conference paper
Antithrombin — Diagnostik und Therapie

  • 25 Accesses

Zusammenfassung

Die zur Substitutionstherapie eingesetzten Antithrombinkonzentrate werden aus Humanplasma hergestellt. Seit Einführung des Begriffs Antithrombin wurde mehrere Male versucht, Antithrombin anzureichern, doch erst 1967 stellten Abildgaard und Heimburger zwei Methoden vor, die zu praktischen Ergebnissen führten [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abildgaard U (1967) Purification of two progressive antithrombins of human plasma. Scand J Clin Lab Invest 19:190

    Article  Google Scholar 

  2. Heimburger N (1967) First Int Symp Tissue Factors in the Hemostasis of the Coagulation-Fibrinolysis System. Firenze, 353

    Google Scholar 

  3. Miller-Andersson M, Borg H, Andersson L-0 (1974) Purification of anti-thrombin III by affinity chromatography. Thromb Res 5:439

    Article  CAS  Google Scholar 

  4. Abildgaard U (1978) Personal communication

    Google Scholar 

  5. Schramm W (1983) Erfahrungen mit der Substitution von Antithrombin-III-Konzentraten bei angeborenen und erworbenen Mangelzuständen. Behring Inst Mitt 73:66

    PubMed  Google Scholar 

  6. Hellgren M, Tengborn L, Abildgaard U (1982) Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 14:127

    Article  PubMed  CAS  Google Scholar 

  7. Javelin L (1990) Prophylactic and therapeutic use of antithrombin-III concentrates, in The biology of antithrombins, Sas G., for Library of Congress, Sas G., Editor, 135

    Google Scholar 

  8. Marciniak E, Gockerman JP (1977) Heparin-induced decrease in circulating antithrombin III. Lancet 2:581

    Article  PubMed  CAS  Google Scholar 

  9. Conard J, Horellou MH, van Dresden P, Samama M (1987) Pregnancy and congenital deficiency in antithrombin III or protein C. Thromb Haemost 58:39

    Google Scholar 

  10. Brandt P (1981) Observations during the treatment of antithrombin III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion. Thromb Res 22:15

    Article  PubMed  CAS  Google Scholar 

  11. Tengborn L, Bengtsson T (1986) Antithrombin III concentrate. Thrombo-prophylaxis during pregnancy in a patient with congenital antithrombin III deficiency. Acta Obstet Gynecol Scand 65:375

    Article  PubMed  CAS  Google Scholar 

  12. Boyer C, Wolf M, Lavergne JM, Haiat A, Declere A, Franco D, Larrieu MJ (1980) Prevention of disseminated intravascular coagulation after LeVeen peritoneovenous shunts by infusions of AT III concentrate, in Proc Sixth Int Congr on Thrombosis of the Mediterranean League against Thromboembolic Disease, Monte Carlo

    Google Scholar 

  13. Büller HR, ten Cate JW (1983) Antithrombin III infusion in patients undergoing peritoneovenous shunt operation: failure in the prevention of disseminated intravascular coagulation. Thromb Haemost 49:128

    PubMed  Google Scholar 

  14. Schipper HG, Kahlé LH, Jenkins CS, ten Cate JW (1978) Antithrombin Ill-transfusion in disseminated intravascular coagulation. Lancet 1:854

    Article  PubMed  CAS  Google Scholar 

  15. Schipper HG, ten Cate JW (1982) Antithrombin III-transfusion in patients with hepatic cirrhosis. Br J Haematol 52:25

    Article  PubMed  CAS  Google Scholar 

  16. Brandt P, Jespersen J, Gregersen G (1981) Post-partum haemolytic-uraemic syndrome treated with antithrombin III. Nephron 27:15

    Article  PubMed  CAS  Google Scholar 

  17. Büller HR, Weenink AH, Treffers PE, Kahlé LH, Otten HA, ten Cate JW (1980) Severe antithrombin III deficiency in a patient with preeclampsia. Observations on the effect of human AT III concentrate transfusion. Scand J Haematol 25:81

    Article  PubMed  Google Scholar 

  18. Haak HL, Stolk JC, Gratama JW, van Hulsteyn H, Briet E (1982) Use of antithrombin concentrate in stable diffuse intravascular coagulation. Acta Haematol 68:28

    Article  PubMed  CAS  Google Scholar 

  19. Hellgren M, Hägnevik K, Robbe H, Björk O, Blombäck M, Eklund J (1983) Severe acquired antithrombin III deficiency in relation to hepatic and renal insufficiency and intrauterine fetal death in late pregnancy. Gynecol Obstet Invest 16:107

    Article  PubMed  CAS  Google Scholar 

  20. Jespersen J, Rasmussen NR, Toftgaard C (1982) Observations during the treatment with antithrombin-III concentrate of a case of tampon-related toxic shock syndrome and disseminated intravascular coagulation. Discrepancies between functional and immunologic determinations of antithrombin. Thromb Res 26:457

    CAS  Google Scholar 

  21. Laursen B, Mortensen JZ, Frost L, Hansen KB (1981) Disseminated intravascular coagulation in hepatic failure treated with antithrombin III. Thromb Res 22:701

    Article  PubMed  CAS  Google Scholar 

  22. Mosvold J, Abildgaard U, Jenssen H, Andersen R (1982) Low antithrombin III in acute hepatic failure at term. Scand J Haematol 29:48

    Article  PubMed  CAS  Google Scholar 

  23. Weenink GH, Büller HR, ten Cate JW, Smorenberg-Schoorl ME, Schutte MF, Trefferts PE (1980) Severely impaired hemostasis in a preeclampic patient successfully treated with human AT III concentrate and platelet transfusion, in Studies of Antithrombin III and Human Antithrombin III Concentrate Transfusion. Büller HR, ed. Thesis, Wilhelmina Gasthuis, Amsterdam

    Google Scholar 

  24. Hellgren M, Robbe H, Hägnevik K, Faxelius G (1984) Antithrombin as adjuvant in the treatment of acquired antithrombin deficiency during pregnancy and delivery, IV World Congr Int Soc. The Study of Hypertension in Pregnancy, Amsterdam; Abstr 152

    Google Scholar 

  25. Hellgren M, Javelin L, Hägnevik K, Blombäck M, Medén-Britth G (1984) Antithrombin III concentrate as adjuvant in DIC treatment — a pilot study in 9 severely ill patients. Thromb Res 35:459

    Article  PubMed  CAS  Google Scholar 

  26. Potron G, Leroux B, Droulle C, Santepne B, Poynard A (1983) Efficiency of antithrombin treatment in newborn infants with respiratory distress syndrome. Thromb Haemost 50:48

    Google Scholar 

  27. Smith-Erichsen N, Aasen AO, Kongsgaard UE, Bakka A, Bergan A, Bjerkelund CE, Flatmark A, Moen H, Raedder M, Rosseland A, Röise O, Sivertsen S, Skulberg A, Solheim K, Stadaas JA, Sunde S, Vaagenes P (1996) The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. Clin Int Care 7:291

    Article  Google Scholar 

  28. Albert J (1992) Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 36:745

    Article  PubMed  CAS  Google Scholar 

  29. Inthorn D, Storck M, Jochum M (1991) Antithrombin-III in der Therapie des septischen Organversagens. Ergebnisse einer prospektiven Studie. Intensivmed 28:434

    Google Scholar 

  30. Eigl J (1992) Data on file. Pharmacia & Upjohn AB

    Google Scholar 

  31. Kesteven PJ, Ahmed A, Williams BT, Savidge GF (1985) Antithrombin III concentrates in cardiopulmonary bypass. Thromb Haemost 54:89

    Google Scholar 

  32. Grip L, Blombäck M, Egberg N, Olsson Å, Svane B, Velander M (1995) Antithrombin III supplementation to patients undergoing PTCA for unstable angina pectoris. Thromb Haemost 73:6, 1250, Abstr. 1339

    Google Scholar 

  33. Eriksson B (1997) A double virus-inactivated and highly purified antithrombin III concentrate. Suppl to Schock 7:162, Abstr. 651

    Google Scholar 

  34. Horowitz B, Prince AM, Hamman J, Watklevicz C (1994) Viral safety of solvent-detergent-treated blood products. Blood Coagulation and Fibrinolysis 5 (Suppl 3):21

    Article  Google Scholar 

  35. Lindholm A (1994) Epidemiology of viral infections in the Swedish blood-donor population. Blood Coagulation and Fibrinolysis 5 (Suppl 3): 13

    Article  Google Scholar 

  36. Arnberg H, Ryde L, Widlund L, Vietorisz A (1997) Comparison of pharmacokinetics and tolerability of ATenativ® with solvent/detergent treatment, Gesellschaft für Thrombose- und Hämostaseforschung e.V., Wien

    Google Scholar 

Download references

Authors
  1. L. Javelin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. II. Medizinische Klinik und Poliklinik, Univerasitätsklinikum Mainz, Langenbeckstraße 1, D-55131, Mainz, Germany

    L. S. Weilemann  & H. Schinzel  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Javelin, L. (1998). ATenativ® — ein hochreines Antithrombinkonzentrat. In: Weilemann, L.S., Schinzel, H. (eds) Antithrombin — Diagnostik und Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60305-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60305-1_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63635-9

  • Online ISBN: 978-3-642-60305-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation